Vanguard Group Inc Acurx Pharmaceuticals, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Acurx Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 529,349 shares of ACXP stock, worth $206,446. This represents 0.0% of its overall portfolio holdings.
Number of Shares
529,349
Previous 529,349
-0.0%
Holding current value
$206,446
Previous $428,000
51.87%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ACXP
# of Institutions
27Shares Held
3.49MCall Options Held
100Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ2.04MShares$797,3726.36% of portfolio
-
Prospect Financial Services LLC Melville, NY367KShares$142,9640.08% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$66,8790.0% of portfolio
-
Morgan Stanley New York, NY106KShares$41,4180.0% of portfolio
-
Vanguard Capital Wealth Advisors67.5KShares$26,3250.03% of portfolio
About Acurx Pharmaceuticals, Inc.
- Ticker ACXP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,556,600
- Market Cap $4.51M
- Description
- Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The com...